Abstract
Introduction: The association of serum sex hormone-binding globulin (SHBG) concentrations with dementia risk remains uncertain in middle-aged to older women. We examined associations of serum SHBG levels with incidence of all-cause dementia and its subtypes in middle-aged to older women from the large population-based UK Biobank cohort study. Methods: Serum total SHBG levels were measured by immunoassay. The incidence of all-cause dementia and its subtypes was recorded. Cox proportional hazards models were used to calculate hazard ratios (HR) for main outcomes. Results: Among 171,482 community-dwelling women (mean [SD] age was 59.9 [5.4] years, median follow-up of 11.8 years), 2,368 developed dementia, including 1,088 from Alzheimer’s disease (AD), 451 from vascular dementia (VAD), and 1,609 from other dementia. After multivariable adjustments, higher serum SHBG levels were significantly associated with higher risks of all-cause dementia, AD, and other dementia (all p < 0.05). Compared to those in the lowest quartile of SHBG levels, participants in the highest quartile of SHBG levels had a higher risk of all-cause dementia (HR: 1.34; 95% confidence interval [CI]: 1.16–1.53), AD (HR: 1.32; 95% CI: 1.07–1.62), and other dementia (HR: 1.44; 95% CI: 1.21–1.70). However, this relationship was not significant for VAD (HR: 1.16; 95% CI: 0.86–1.56). Conclusion: These findings indicated that higher serum SHBG concentrations were independently associated with higher risks of incident all-cause dementia, as well as AD and other dementia among middle-aged to older women. No association was found for VAD.
Journal Section:
Research Article
References
1.
Gale SA, Acar D, Daffner KR. Dementia. Am J Med. 2018 Oct;131(10):1161–9.
2.
Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–46.
3.
Li R, Singh M. Sex differences in cognitive impairment and Alzheimer’s disease. Front Neuroendocrinol. 2014 Aug;35(3):385–403.
4.
Laws KR, Irvine K, Gale TM. Sex differences in cognitive impairment in Alzheimer’s disease. World J Psychiatry. 2016 Mar 22;6(1):54–65.
5.
Kim MY, Kim K, Hong CH, Lee SY, Jung YS. Sex differences in cardiovascular risk factors for dementia. Biomol Ther. 2018 Nov 1;26(6):521–32.
6.
McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain: implications for cognition and aging. Neurology. 1997 May;48(5 Suppl 7):S8–15.
7.
McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev. 1999 Jun;20(3):279–307.
8.
Yaffe K, Lui LY, Grady D, Cauley J, Kramer J, Cummings SR. Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet. 2000 Aug 26;356(9231):708–12.
9.
Greenfield JP, Leung LW, Cai D, Kaasik K, Gross RS, Rodriguez-Boulan E, et al. Estrogen lowers Alzheimer beta-amyloid generation by stimulating trans-Golgi network vesicle biogenesis. J Biol Chem. 2002 Apr 5;277(14):12128–36.
10.
Gong J, Harris K, Peters SAE, Woodward M. Reproductive factors and the risk of incident dementia: a cohort study of UK Biobank participants. PLoS Med. 2022 Apr;19(4):e1003955.
11.
Hammond GL. Potential functions of plasma steroid-binding proteins. Trends Endocrinol Metab. 1995 Nov-Dec;6(9–10):298–304.
12.
de Ronde W, van der Schouw YT, Muller M, Grobbee DE, Gooren LJ, Pols HA, et al. Associations of sex-hormone-binding globulin (SHBG) with non-SHBG-bound levels of testosterone and estradiol in independently living men. J Clin Endocrinol Metab. 2005 Jan;90(1):157–62.
13.
Schupf N, Pang D, Patel BN, Silverman W, Schubert R, Lai F, et al. Onset of dementia is associated with age at menopause in women with Down’s syndrome. Ann Neurol. 2003 Oct;54(4):433–8.
14.
Hoskin EK, Tang MX, Manly JJ, Mayeux R. Elevated sex-hormone binding globulin in elderly women with Alzheimer’s disease. Neurobiol Aging. 2004 Feb;25(2):141–7.
15.
Paoletti AM, Congia S, Lello S, Tedde D, Orrù M, Pistis M, et al. Low androgenization index in elderly women and elderly men with Alzheimer’s disease. Neurology. 2004 Jan 27;62(2):301–3.
16.
Schupf N, Winsten S, Patel B, Pang D, Ferin M, Zigman WB, et al. Bioavailable estradiol and age at onset of Alzheimer’s disease in postmenopausal women with Down syndrome. Neurosci Lett. 2006 Oct 9;406(3):298–302.
17.
Muller M, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Sex hormone binding globulin and incident Alzheimer’s disease in elderly men and women. Neurobiol Aging. 2010 Oct;31(10):1758–65.
18.
Lin KA, Rundel C, Doraiswamy PM; Alzheimer’s Disease Neuroimaging Initiative. Serum SHBG levels are not associated with longitudinal cognitive decline in mild cognitive impairment. J Alzheimers Dis. 2017;55(3):1123–30.
19.
Xu W, Su BJ, Shen XN, Bi YL, Tan CC, Li JQ, et al. Plasma sex hormone-binding globulin predicts neurodegeneration and clinical progression in prodromal Alzheimer’s disease. Aging. 2020 Jul 22;12(14):14528–41.
20.
Collins R. What makes UK Biobank special?Lancet. 2012 Mar 31;379(9822):1173–4.
21.
Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015 Mar;12(3):e1001779.
22.
Bush KWT, Schnier C, Nolan J, Sudlow C. Definitions of dementia and the major diagnostic pathologies, UK Biobank Phase 1 outcomes adjudication. Version 1.0; 2020. Available from: https://biobankndphoxacuk/showcase/showcase/docs/alg_outcome_dementiapdf [Accessed 16 September 2020].
23.
Davies G, Harris SE, Reynolds CA, Payton A, Knight HM, Liewald DC, et al. A genome-wide association study implicates the APOE locus in nonpathological cognitive ageing. Mol Psychiatry. 2014 Jan;19(1):76–87.
24.
Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. APOE and dementia: resequencing and genotyping in 105,597 individuals. Alzheimers Dement. 2020 Dec;16(12):1624–37.
25.
Marriott RJ, Murray K, Flicker L, Hankey GJ, Matsumoto AM, Dwivedi G, et al. Lower serum testosterone concentrations are associated with a higher incidence of dementia in men: the UK Biobank prospective cohort study. Alzheimers Dement. 2022 Oct;18(10):1907–18.
26.
Xing Y, Qin W, Li F, Jia XF, Jia J. Associations between sex hormones and cognitive and neuropsychiatric manifestations in vascular dementia (VaD). Arch Gerontol Geriatr. 2013 Jan-Feb;56(1):85–90.
27.
Selby C. Sex hormone binding globulin: origin, function and clinical significance. Ann Clin Biochem. 1990 Nov;27(Pt 6):532–41.
28.
Lecomte P, Lecureuil N, Lecureuil M, Lemonnier Y, Mariotte N, Valat C, et al. Sex differences in the control of sex-hormone-binding globulin in the elderly: role of insulin-like growth factor-I and insulin. Eur J Endocrinol. 1998 Aug;139(2):178–83.
29.
Muller M, den Tonkelaar I, Thijssen JH, Grobbee DE, van der Schouw YT. Endogenous sex hormones in men aged 40-80 years. Eur J Endocrinol. 2003 Dec;149(6):583–9.
30.
Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev. 1989 Aug;10(3):232–74.
31.
Wilkinson T, Schnier C, Bush K, Rannikmäe K, Henshall DE, Lerpiniere C, et al. Identifying dementia outcomes in UK Biobank: a validation study of primary care, hospital admissions and mortality data. Eur J Epidemiol. 2019 Jun;34(6):557–65.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
